Clinuvel Pharmaceuticals (CUVL) vs Indaptus Therapeutics (INDP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Clinuvel Pharmaceuticals (CUVL) has outperformed Indaptus Therapeutics (INDP) over the past year, losing 29.7% versus a loss of 38.8%. Over five years, CUVL leads with a -80.9% price change compared with -99.0% for INDP. Indaptus Therapeutics is the larger company by market cap ($315.8 million vs $282.7 million), about 1.1 times the size.
Clinuvel Pharmaceuticals pays a dividend yielding 0.89%, while Indaptus Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUVL | INDP |
|---|---|---|
| Share price | $5.60 | $2.37 |
| Market cap | $282.73M | $315.78M |
| 1-day change | -3.45% | +4.87% |
| YTD return | -31.60% | -22.34% |
| 1-year return | -29.70% | -38.75% |
| 5-year return | -80.95% | -98.97% |
| P/E ratio (TTM) | 12.44 | — |
| EPS (TTM) | $0.45 | $-6.15 |
| Dividend yield | 0.89% | 0.00% |
| Annual dividend | $0.05 | $0.00 |
| 52-week high | $8.92 | $5.96 |
| 52-week low | $5.53 | $0.92 |
| Distance from 52-week high | -37.22% | -60.23% |
| Average volume | 12.84K | 829.14K |
| Shares outstanding | 50.49M | 133.24M |
| Employees | — | 5 |
| Sector | Miscellaneous | Health Care |
| Industry | Miscellaneous | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Clinuvel Pharmaceuticals in Miscellaneous and Indaptus Therapeutics in Health Care.
About Clinuvel Pharmaceuticals
CUVL stock →Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Miscellaneous · Miscellaneous
About Indaptus Therapeutics
INDP stock →Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
CUVL vs INDP FAQ
Which is bigger, Clinuvel Pharmaceuticals or Indaptus Therapeutics?
Indaptus Therapeutics (INDP) is larger, with a market capitalization of $315.78M compared with $282.73M for Clinuvel Pharmaceuticals (CUVL).
Which stock has performed better over the past year, CUVL or INDP?
CUVL returned -29.70% over the past 12 months, compared with -38.75% for INDP (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Clinuvel Pharmaceuticals or Indaptus Therapeutics?
Clinuvel Pharmaceuticals pays a dividend yielding 0.89%, while Indaptus Therapeutics does not currently pay a regular dividend.
Are Clinuvel Pharmaceuticals and Indaptus Therapeutics in the same industry?
No. Clinuvel Pharmaceuticals is in the Miscellaneous sector, while Indaptus Therapeutics is in Health Care.